Innovent Biologics's market cap is currently HK$172.47B. The company's EPS TTM is HK$0.5562038529000001; its P/E ratio is 135.57; Innovent Biologics is scheduled to report earnings on August 27, 2025, and the estimated EPS forecast is HK$0.04. See an overview of income statement, balance sheet, and cash flow financials.
